For the quarter ended September 2025, Myriad Genetics (MYGN) reported revenue of $205.7 million, down 3.6% over the same period last year. EPS came in at $0, compared to $0.06 in the year-ago quarter.
The reported revenue represents a surprise of +0.24% over the Zacks Consensus Estimate of $205.21 million. With the consensus EPS estimate being -$0.01, the EPS surprise was +100%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Myriad performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue by core product- Prenatal: $44.5 million compared to the $47.92 million average estimate based on two analysts. The reported number represents a change of +2.3% year over year.
- Revenue by core product- Hereditary Cancer: $93 million compared to the $93.53 million average estimate based on two analysts. The reported number represents a change of +2.8% year over year.
- Revenue by core product- Pharmacogenomics: $38.7 million versus $34.8 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -18.9% change.
- Revenue by core product- Tumor Profiling: $29.5 million versus $29.11 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -6.7% change.
View all Key Company Metrics for Myriad here>>>
Shares of Myriad have returned -0.3% over the past month versus the Zacks S&P 500 composite's +2.4% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Myriad Genetics, Inc. (MYGN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
